The DOI matches its Crossref record.
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Open accessAbstract
The potential negative impact of HLA class I antigen abnormalities on the outcome of T cell-based immunotherapy of melanoma has prompted us to investigate the mechanisms underlying lack of HLA class I antigen expression by melanoma cell lines Me18105, Me9923, and Me1386. Distinct mutations in the beta2-microglobulin (beta2m) gene were identified in each cell line which result in loss of functional beta2m. In Me18105 cells, an aberrant splicing mechanism caused by an A--> G point mutation in the splice acceptor site of intron 1 of the beta2m gene, deletes 11 bp from the beta2m mRNA creating a shift in the reading frame. In Me9923 cells a 14-bp deletion in exon 2 and in Me1386 cells a CT deletion in exon 1 of the beta2m gene produce a frameshift mutation. The beta2m gene mutations identified in Me18105, Me9923, and Me1386 cells were also detected in the surgically removed melanoma lesions from which the cell lines originated. Transfection of each melanoma cell line with a wild-type beta2m gene restored HLA class I antigen expression and, in Me18105 cells, recognition by Melan-A/MART-1-specific, HLA-A2-restricted cytotoxic T lymphocytes. Interestingly, the beta2m mutation present in Me9923 cells that were derived from a metastatic lesion was also found in the Me9923P cell line that originated from the autologous primary lesion. These data suggest that beta2m mutations in melanoma cells may be an early event in progression to the malignant phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“…with drugs as monotherapy (including monoclonal antibodies), the majority of contemporary approaches focus on combination strategies in an effort to overcome resistance associated with treatment with single-pronged efforts (Table 3) (Hicklin et al., 1998; Moon et al., 2014; Ninomiya et al., 2015).”
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Self-citationNatural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Hong, F., Yan, J., Baran, J. T., Allendorf, D. J., Hansen, R. D., Ostroff, G. R., Xing, P. X., Cheung, N.-K. V., & Ross, G. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.797 · Cited by 472
Challa-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
Hicklin, D. J., Marincola, F. M., & Ferrone, S. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01451-3 · Cited by 376
Self-citationAntiinflammatory and Immunomodulating Properties of FungalMetabolites
Lull, C., Wichers, H. J., & Savelkoul, H. F. J. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.63 · Cited by 346
Zhu, X., Meng, G., Dickinson, B. L., Li, X., Mizoguchi, E., Miao, L., Wang, Y., Robert, C., Wu, B., Smith, P. D., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3266 · Cited by 322
Yang, E. V., Kim, S.-J., Donovan, E. L., Chen, M., Gross, A. C., Webster Marketon, J. I., Barsky, S. H., & Glaser, R. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.10.005 · Cited by 317
MHC antigens and tumor escape from immune surveillance
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305
Stem cell medicine encounters the immune system
Bradley, J. A., Bolton, E. M., & Pedersen, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri934 · Cited by 290
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., Arancia, G., Anichini, A., Fais, S., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18809.x · Cited by 289
Self-citationKoopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.961 · Cited by 279
HLA class I antigen abnormalities and immune escape by malignant cells
Seliger, B., Cabrera, T., Garrido, F., & Ferrone, S. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0404 · Cited by 270
Self-citationHLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253
Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187
Tsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148
MHC Class I Antigens and Immune Surveillance in Transformed Cells
Aptsiauri, N., Cabrera, T., Garcia‐Lora, A., Lopez‐Nevot, M. A., Ruiz‐Cabello, F., & Garrido, F. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(07)56005-5 · Cited by 145
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity
Falahat, R., Perez-Villarroel, P., Mailloux, A. W., Zhu, G., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0229 · Cited by 95
Bissonnette, R. P., Cesario, R. M., Goodenow, B., Shojaei, F., & Gillings, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08702-x · Cited by 24
Metadata
- Authors
- Hicklin, D. J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., & Ferrone, S.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-06-15
- Volume
- 101
- Issue
- 12
- Pages
- 2720-2729
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2066960417
- Cited by
- 198
- References
- 0
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.